Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2012
10/11/2012US20120258966 Pharmaceutical compounds
10/11/2012US20120258962 1,3-oxazines as bace1 and/or bace2 inhibitors
10/11/2012US20120258960 Novel multifunctional peptidase inhibitors, especially for medical use
10/11/2012US20120258959 Pyridone gpr119 g protein-coupled receptor agonists
10/11/2012US20120258958 Azaindoles useful as inhibitors of jak and other protein kinases
10/11/2012US20120258954 ArylSulfonamide Based Matrix Metalloprotease Inhibitors
10/11/2012US20120258953 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
10/11/2012US20120258952 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors
10/11/2012US20120258949 Spirocyclic derivatives as histone deacetylase inhibitors
10/11/2012US20120258941 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases
10/11/2012US20120258940 Method for treating haematological cancers
10/11/2012US20120258938 Enzymatic Production or Chemical Synthesis and Uses for 5,7-Dienes and UVB Conversion Products Thereof
10/11/2012US20120258933 Combination
10/11/2012US20120258927 Inhibitors of e1 activating enzymes
10/11/2012US20120258923 BIOACTIVITY COMPOSITION OF Reevesia formosana
10/11/2012US20120258920 Peptides and aptamers thereof as specific modulators of mutant p53 function
10/11/2012US20120258917 Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
10/11/2012US20120258911 Phenylalkylcarboxylic acid delivery agents
10/11/2012US20120258182 Synergistic compositions and methods
10/11/2012US20120258181 Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents
10/11/2012US20120258176 Nanoparticles for protein drug delivery
10/11/2012US20120258163 Tyrosine Kinase Microspheres
10/11/2012US20120258147 Method for inhibiting angiogenesis
10/11/2012US20120258134 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
10/11/2012US20120258122 Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 and Uses Thereof
10/11/2012US20120258121 Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
10/11/2012US20120258119 Anti-fibroblast activation protein antibodies and methods and uses thereof
10/11/2012US20120258117 Methods and compositions for modulation of histone ubiquitination
10/11/2012US20120258116 Method for inducing cancer cell apoptosis or inhibiting the cancer cell migration
10/11/2012US20120258115 Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms
10/11/2012US20120258114 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
10/11/2012US20120258113 Susbstantially pure steroidogenesis inducing peptide and uses thereof
10/11/2012US20120258110 Fdf03 antibodies and uses thereof
10/11/2012US20120258108 Dual Variable Domain Immunoglobulins and Uses Thereof
10/11/2012US20120258107 Agents, Uses and Methods
10/11/2012US20120258106 Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
10/11/2012US20120258102 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibodies
10/11/2012US20120258101 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
10/11/2012US20120258099 Inhibitors of guanine exchange factors and their use as anticancer drugs
10/11/2012US20120258096 Anti-d monoclonal antibodies
10/11/2012US20120258092 Optimized Fc Variants
10/11/2012US20120258091 Genetic products differentially expressed in tumors and the use thereof
10/11/2012US20120258085 Expansion of NK Cells
10/11/2012US20120258082 Production of ifn-lambda by conventional dendritic cells and uses thereof
10/11/2012US20120258081 Methods of treating proliferative diseases
10/11/2012US20120258080 Pyridopyrazine derivatives and their use
10/11/2012US20120258073 Immunotherapy
10/11/2012US20120258071 Compositions and Methods of Use for MGD-CSF in Disease Treatment
10/11/2012US20120258056 Treatment of cancer and compositions
10/11/2012US20120258045 Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
10/11/2012US20120258043 Linkable Lewis X Analogs
10/11/2012US20120258042 Combined use of tgf-b signaling inhibitor and antitumor agent
10/11/2012US20120258040 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
10/11/2012US20120258039 Treatment of tumors using specific anti-l1 antibody
10/11/2012US20120258038 Uses of apoptotic cell-targeting peptides, label substances and liposomes containing a therapeutic agent for preventing, treating or therapeutically diagnosing apoptosis-related diseases
10/11/2012CA2834734A1 Methods of improving vaccine immunogenicity
10/11/2012CA2832783A1 Zinc n-acetyl taurinate for the treatment of prostate cancer
10/11/2012CA2832569A1 Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
10/11/2012CA2832540A1 Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
10/11/2012CA2832439A1 Migrastatins and uses thereof
10/11/2012CA2832376A1 Drug containing recombinant mistletoe lectins for treating malignant melanoma
10/11/2012CA2832374A1 Imidazopyridazines as akt kinase inhibitors
10/11/2012CA2832337A1 Pyridopyrazine derivatives and their use
10/11/2012CA2832321A1 Pyridopyrazine derivatives and their use
10/11/2012CA2832310A1 Substituted imidazopyridines and intermediates thereof
10/11/2012CA2832291A1 Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors
10/11/2012CA2832123A1 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
10/11/2012CA2832120A1 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
10/11/2012CA2832115A1 Pepducin design and use
10/11/2012CA2832113A1 Hepatocyte growth factor mimics as therapeutic agents
10/11/2012CA2832100A1 Aminopyrazine compounds useful as inhibitors of tra kinase
10/11/2012CA2831535A1 Oral enzyme compositions for intestinal delivery
10/11/2012CA2831474A1 New indolinone protein kinase inhibitors
10/11/2012CA2830367A1 Novel imidazo-oxazine compound or salt thereof
10/11/2012CA2826785A1 Inhibitors of phosphatidic acid phosphohydrolase (pap), including d-propranolol and analogs thereof, alone or in combination with desipramine, for the treatment of cancers that depend on the epidermal growth factor receptor (egfr), oncogenic variants thereof and other members of the erbb/her family
10/10/2012EP2508606A1 Partial fragment of REIC/Dkk-3 gene and therapeutic agent for cancer containing the same
10/10/2012EP2508601A2 Tem8 peptides and vaccines comprising the same
10/10/2012EP2508536A1 Cytotoxicity mediation of cells evidencing surface expression of CD44
10/10/2012EP2508528A1 Stereoselective synthesis of beta-nucleosides
10/10/2012EP2508526A1 Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators
10/10/2012EP2508525A1 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
10/10/2012EP2508523A2 Polymorphs of dasatinib and process for preparation thereof
10/10/2012EP2508521A2 Method for the production of amino crotonyl compounds
10/10/2012EP2508512A1 Novel N,N'-hydrazino-bis-isatin derivatives with selective activity against multidrug-resistant cancer cells
10/10/2012EP2508510A1 Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof
10/10/2012EP2508195A1 Medicine containing recombinant mistellectins for treating malignant melanoma
10/10/2012EP2508190A1 Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages
10/10/2012EP2508185A1 Anti-tumor effect potentiator
10/10/2012EP2508184A1 Pyridopyrazine derivatives and their use
10/10/2012EP2508171A1 Pharmaceutical magnetic nano-particle composition
10/10/2012EP2508170A1 Liposome of irinotecan or its hydrochloride and preparation method thereof
10/10/2012EP2507374A2 Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors
10/10/2012EP2507257A1 Mybl2 peptides and vaccines containing the same
10/10/2012EP2507256A1 Imp-3 oligopeptides and vaccines including the same
10/10/2012EP2507253A2 6-substituted estradiol derivatives and methods of use
10/10/2012EP2507243A1 Spiroindolinone pyrrolidines
10/10/2012EP2507241A1 Methanocarba adenosine derivatives and dendrimer conjugates thereof
10/10/2012EP2507236A1 Triazolopyridine derivatives
10/10/2012EP2507235A1 Triazolopyridines
10/10/2012EP2507233A1 Substituted triazolopyridines
1 ... 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 ... 2211